First Racial-Ethnic Breast and Cervical Cancer Screening Data

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

WASHINGTON-A new analysis of data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) shows that among women who received their first NBCCEDP Pap test between 1991 and 1998, American Indian and Alaskan Native (AI/AN) women had the highest proportion of abnormal Pap tests, while white women had the highest rate of serious cervical lesions detected by biopsy.

WASHINGTON—A new analysis of data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) shows that among women who received their first NBCCEDP Pap test between 1991 and 1998, American Indian and Alaskan Native (AI/AN) women had the highest proportion of abnormal Pap tests, while white women had the highest rate of serious cervical lesions detected by biopsy.

Specifically, 4.4% of AI/AN women, 3.2% of blacks, 3.0% of whites, 2.7% of Hispanics, and 1.9% of Asian and Pacific Islanders (A/PIs) had abnormal tests. Biopsies detected serious cervical lesions in 9.9 per 1,000 Pap tests among whites, followed by Hispanics with 7.6 per 1,000, blacks at 7.1 per 1,000, AI/AN women with 6.7 per 1,000, and A/PIs at 5.4 per 1,000 Pap tests.

AI/AN women were the least likely to have ever had a Pap test prior to participating in a NBCCEDP screening. Black women were the least likely to receive follow-up care after a diagnosis of a serious cervical lesion.

NBCCEDP, which is administered by the CDC, is a federally funded program that provides breast and cervical cancer screenings to older and low-income women, and underserved women of racial and ethnic minority groups.

Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Related Content